

SymBio Announces Pricing of Secondary Offering and Overallotment

TOKYO, Japan, November 27, 2013 -- SymBio Pharmaceuticals Limited (JASDAQ: 4582, hereinafter referred to as “the Company”) announced today it has determined the issue price, the selling price and other matters in relation to the issuance of new shares and the secondary offering of shares of the Company, which were resolved at the Company’s Board of Directors Meeting held on November 19, 2013.

The details of these determinations are as stated below.

1. Summary of Fund Raising

(1) New share issue through the public offering

(1) Issue Price	400 JPY per share
(2) Total Amount of Issue Price	2,688,080,000JPY
(3) Amount to be paid	372.57JPY per share
(4) Total amount to be paid	2,503,744,914JPY
(5) Amount of capital and paid-in capital to be increased	Capital increase :1,251,872,457 JPY Additional paid-in capital increase :1,251,872,457 JPY
(6) Subscription Period	From Thursday, November 28, 2013 to Friday, November 29, 2013
(7) Payment Date	Wednesday, December 4, 2013
(8) Delivery Date	Thursday, December 5, 2013
(9) Others	SMBC Nikko Securities Inc. will underwrite and purchase at the amount to be paid and offer at the issue price (offer price).

(2) Secondary Offering (Over-allotments)

(1) Number of shares of secondary offering	1,008,000 shares
(2) Secondary offering price	400JPY per share
(3) Total amount of the secondary offering price	403,200,000JPY
(4) Subscription Period	From Thursday, November 28, 2013 to Friday, November 29, 2013
(5) Delivery Date	Thursday, December 5, 2013

Note: This press release has been prepared for the sole purpose of publicly announcing certain matters relating to the Offering of shares of the Company and not for the purpose of soliciting investment or engaging in any other similar activity. This press release does not constitute an offer of any securities for sale within or outside Japan. Additionally, this press release is not an offer of securities for sale in the United States. The securities have not and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. No offering of securities in the United States will be made in connection with the above mentioned transactions.

(3) Issuance of new shares by way of third party allotment

(1) Amount to be paid	372.57JPY per share
(2) Total amount to be paid	Maximum 375,550,560JPY
(3) Amount of capital and paid-in capital to be increased	Capital increase : 187,775,280JPY Additional paid-in capital increase : 187,775,280JPY
(4) Subscription Period	Tuesday, December 24, 2013
(5) Payment Date	Wednesday, December 25, 2013

2. Calculation of Issue price and Secondary offering price

(1) Base Date for calculation and price per share on the Base Date:

Wednesday, November 27, 2013, 422JPY

(2) Discount Rate : 5.21%

3. Syndicate covering transaction period:

From Saturday, November 30, 2013 to Thursday, December 19, 2013

4. Use of Funds Raised

This fund will be allocated during a period from January, 2014 through December, 2015 toward development expenses for SyB L-1101 (rigosertib, intravenous) for treating relapsed and refractory Myelodysplastic Syndromes (MDS) and SyB C-1101 (rigosertib, oral agent) for the initial treatment of MDS. Proceeds will also be used to fund development and milestone payments for SyB L/C-1101 (rigosertib, intravenous and oral agent) in additional indications outside of MDS.

Until specific financial needs arise, it is our policy to manage this fund by, among other methods, investing it in low risk financial instruments.

About Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes represent a group of diverse myeloid (bone marrow) stem cell disorders that gradually affect the ability of bone marrow to produce red blood cells, white blood cells and platelets sufficiently. Blood stem cells fail to mature into healthy blood cells, and the immature blood cells, called blasts, do not function normally and either die in the bone marrow or enter the blood. A higher percent of blasts is linked to a higher likelihood of developing acute myeloid leukemia and poorer overall prognosis. The risk of MDS increases with age and the disease commonly affects the elderly. In Japan, the number of the patients is estimated to be around 11,000 (according to the survey of patients by the Ministry of Health, Labour and Welfare in 2011). At present, there is only one therapeutic agent sold as a treatment for MDS, and therefore the patients are waiting for a new medical agent for the disease to be developed.

Note: This press release has been prepared for the sole purpose of publicly announcing certain matters relating to the Offering of shares of the Company and not for the purpose of soliciting investment or engaging in any other similar activity. This press release does not constitute an offer of any securities for sale within or outside Japan. Additionally, this press release is not an offer of securities for sale in the United States. The securities have not and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. No offering of securities in the United States will be made in connection with the above mentioned transactions.



About Symbio Pharmaceuticals Limited

Symbio Pharmaceuticals was established in March, 2005, by Fuminori Yoshida, who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan (currently Takeda Bio Development Center Limited). The company's underlying corporate mission is "delivering hope to patients in need" as it aspires to be a leading specialty pharmaceutical company in Asia Pacific dedicated to addressing underserved medical needs with focus in oncology, hematology and autoimmune disease.

[Contact]

Tomoyuki Watanabe
Director, Head of Corporate Planning Division
Tel: +081(0)3 5472 1125

Note: This press release has been prepared for the sole purpose of publicly announcing certain matters relating to the Offering of shares of the Company and not for the purpose of soliciting investment or engaging in any other similar activity. This press release does not constitute an offer of any securities for sale within or outside Japan. Additionally, this press release is not an offer of securities for sale in the United States. The securities have not and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. No offering of securities in the United States will be made in connection with the above mentioned transactions.